EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan

Tomoki Sakakida iD, Takeshi Ishikawa, Toshifumi Doi, Ryuichi Morita, Seita Kataoka, Hayato Miyake, Kanji Yamaguchi, Michihisa Moriguchi, Yoshio Sogame, Hiroaki Yasuda, Masahiro Iwasaku, Hideyuki Konishi und 2 weitere

Journal of Gastroenterology · 2023-06 · 58 (6) · 575-585

DOI: 10.1007/s00535-023-01986-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology, 2023-06. Verfasst von Tomoki Sakakida und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, 465 Kajiicho, Hirokoji Agaru, Kawaramachi Street, …. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Special subtypes of pancreatic cancer, such as acinar cell carcinoma (ACC), adenosquamous carcinoma (ASC), and anaplastic carcinoma of the pancreas (ACP), are rare, and so data on them are limited. Using the C-CAT database, we analyzed clinical and genomic characteristics of patients with these and evaluated differences on comparison with pancreatic ductal adenocarcinoma (PDAC) patients.

Methods

We retrospectively reviewed data on 2691 patients with unresectable pancreatic cancer: ACC, ASC, ACP, and PDAC, entered into C-CAT from June 2019 to December 2021. The clinical features, MSI/TMB status, genomic alterations, overall response rate (ORR), disease control rate (DCR), and time to treatment failure (TTF) on receiving FOLFIRINOX (FFX) or GEM + nab-PTX (GnP) therapy as first-line treatment were evaluated.

Results

Numbers of patients with ACC, ASC, ACP, and PDAC were 44 (1.6%), 54 (2.0%), 25 (0.9%), and 2,568 (95.4%), respectively. KRAS and TP53 mutations were prevalent in ASC, ACP, and PDAC (90.7/85.2, 76.0/68.0, and 85.1/69.1%, respectively), while their rates were both significantly lower in ACC (13.6/15.9%, respectively). Conversely, the rate of homologous recombination-related (HRR) genes, including ATM and BRCA1/2, was significantly higher in ACC (11.4/15.9%) than PDAC (2.5/3.7%). In ASC and ACP, no significant differences in ORR, DCR, or TTF between FFX and GnP were noted, while ACC patients showed a trend toward higher ORR with FFX than GnP (61.5 vs. 23.5%, p = 0.06) and significantly more favorable TTF (median 42.3 vs. 21.0 weeks, respectively, p = 0.004).

Conclusions

ACC clearly harbors different genomics compared with PDAC, possibly accounting for differences in treatment efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalHumansAntineoplastic Combined Chemotherapy ProtocolsBRCA1 ProteinRetrospective StudiesJapanBRCA2 ProteinGenomics

Stichwörter der Autor:innen

Acinar cell carcinomaAdenosquamous carcinomaAnaplastic carcinoma of the pancreasGenome analysisPancreatic ductal adenocarcinoma

Substanzen

BRCA1 protein, humanBRCA1 ProteinBRCA2 protein, humanBRCA2 Protein

Autor:innen und Institutionen

  • Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, 465 Kajiicho, Hirokoji Agaru, Kawaramachi Street, Kamigyoku, Kyoto City, Kyoto, 602-8566, Japan.
  • Department of Cancer Genome Medical Center, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, 465 Kajiicho, Hirokoji Agaru, Kawaramachi Street, Kamigyoku, Kyoto City, Kyoto, 602-8566, Japan. iskw-t@koto.kpu-m.ac.jp.
  • Department of Cancer Genome Medical Center, Kyoto Prefectural University of Medicine, Kyoto, Japan. iskw-t@koto.kpu-m.ac.jp.
  • Outpatient Oncology Unit, Kyoto Prefectural University of Medicine, Kyoto, Japan. iskw-t@koto.kpu-m.ac.jp.
  • Outpatient Oncology Unit, Kyoto Prefectural University of Medicine, Kyoto, Japan.

ORCID-Profile: Tomoki Sakakida

Zitieren

APA

Sakakida, T., Ishikawa, T., Doi, T., Morita, R., Kataoka, S., Miyake, H., Yamaguchi, K., Moriguchi, M., Sogame, Y., Yasuda, H., Iwasaku, M., Konishi, H., Takayama, K., & Itoh, Y. (2023). Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan. Journal of Gastroenterology. https://doi.org/10.1007/s00535-023-01986-9

Vancouver

Sakakida T, Ishikawa T, Doi T, Morita R, Kataoka S, Miyake H, et al. Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan. Journal of Gastroenterology. 2023. doi:10.1007/s00535-023-01986-9

BibTeX
@article{Sakakida2023,
  author = {Sakakida, Tomoki and Ishikawa, Takeshi and Doi, Toshifumi and Morita, Ryuichi and Kataoka, Seita and Miyake, Hayato and Yamaguchi, Kanji and Moriguchi, Michihisa and Sogame, Yoshio and Yasuda, Hiroaki and Iwasaku, Masahiro and Konishi, Hideyuki and Takayama, Koichi and Itoh, Yoshito},
  title = {Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan},
  journal = {Journal of Gastroenterology},
  year = {2023},
  doi = {10.1007/s00535-023-01986-9}
}
Kostenlos starten →